Company: AEMD
Filing Date: 2025-01-08
Form Type: 8-K
Source: 0001683168-25-000150
Chunk: 0

Company: AETHLON MEDICAL INC
Filing Date: 2025-01-08
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure
to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously
reported, on June 27, 2024, Aethlon Medical Inc., a Nevada Corporation (the “ Company”) received a letter (the
“ Notice”) from The Nasdaq Stock Market (“ Nasdaq”) advising the Company that for 31 consecutive trading days
preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum
required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)(the “ Minimum Bid Price
Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until December 24,
2024, to regain compliance with the Minimum Bid Requirement.

On January 7, 2025, the
Company received a letter from Nasdaq (the “ Extension Notice”) advising that the Company has been granted a 180-day extension,
or until June 23, 2025, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).
If at any time prior to June 23, 2025, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum
of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement.

The Extension Notice
has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market and does not affect the Company’s
reporting requirements with the Securities and Exchange Commission. If the Company does not regain compliance with the Minimum Bid Price
Requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will
be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth
in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determination
by Nasdaq to the hearings panel, that such appeal would be successful. There can be no assurance that the Company will regain compliance
with the Minimum Bid Price Requirement during the additional 180-day compliance period ending June 23, 2025 or maintain compliance with
any other Nasdaq listing requirement.

The Company intends